Clearside Biomedical Inc.

0.9900-0.0300-2.94%Vol 36.63K1Y Perf -57.68%
Mar 24th, 2023 11:28 DELAYED
BID0.9852 ASK0.9979
Open1.01 Previous Close1.02
Pre-Market1.01 After-Market-
 -0.01 -0.97%  - -
Target Price
6.25 
Analyst Rating
Strong Buy 1.20
Potential %
531.31 
Finscreener Ranking
★★★★+     56.25
Insiders Trans % 3/6/12 mo.
-/-/-75 
Value Ranking
★★★+     52.88
Insiders Value % 3/6/12 mo.
-/-/-77 
Growth Ranking
★★★★+     62.89
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-87 
Income Ranking
 —    -
Price Range Ratio 52W %
3.57 
Earnings Rating
Neutral
Market Cap60.75M 
Earnings Date
10th May 2023
Alpha0.00 Standard Deviation0.33
Beta1.98 

Today's Price Range

0.98501.02

52W Range

0.93002.61

5 Year PE Ratio Range

-5.50-1.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-1.92%
1 Month
-18.40%
3 Months
-10.53%
6 Months
-9.73%
1 Year
-57.68%
3 Years
-32.00%
5 Years
-91.32%
10 Years
-

TickerPriceChg.Chg.%
CLSD0.9900-0.0300-2.94
AAPL158.84-0.0900-0.06
GOOG105.71-0.5500-0.52
MSFT278.851.19000.43
XOM102.63-0.7800-0.75
WFC35.62-0.9900-2.70
JNJ151.880.75000.50
FB196.640.99000.51
GE91.670.07600.08
JPM123.69-3.1500-2.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-16.00
-15.40
-58 945.60
-26.16
RevenueValueIndustryS&P 500US Markets
997.00K
0.02
419.92
297.83
Earnings HistoryEstimateReportedSurprise %
Q04 2022-0.13-0.16-23.08
Q03 20220.04-0.13-425.00
Q02 2022-0.13-0.130.00
Q01 2022-0.03-0.13-333.33
Q04 20210.090.31244.44
Q03 2021-0.09-0.0811.11
Q02 2021-0.12-0.118.33
Q01 2021-0.08-0.13-62.50
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.137.14Positive
12/2022 FY-0.52-44.44Negative
3/2023 QR-0.140.00-
12/2023 FY-0.61-7.02Negative
Next Report Date10th May 2023
Estimated EPS Next Report-0.14
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume36.63K
Shares Outstanding61.36K
Shares Float54.44M
Trades Count90
Dollar Volume36.43K
Avg. Volume161.65K
Avg. Weekly Volume110.22K
Avg. Monthly Volume161.06K
Avg. Quarterly Volume213.69K

Clearside Biomedical Inc. (NASDAQ: CLSD) stock closed at 1.02 per share at the end of the most recent trading day (a 0.99% change compared to the prior day closing price) with a volume of 68.34K shares and market capitalization of 60.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 33 people. Clearside Biomedical Inc. CEO is George Lasezkay.

The one-year performance of Clearside Biomedical Inc. stock is -57.68%, while year-to-date (YTD) performance is -8.93%. CLSD stock has a five-year performance of -91.32%. Its 52-week range is between 0.93 and 2.61, which gives CLSD stock a 52-week price range ratio of 3.57%

Clearside Biomedical Inc. currently has a PE ratio of -27.30, a price-to-book (PB) ratio of 5.32, a price-to-sale (PS) ratio of 97.20, a price to cashflow ratio of 399.40, a PEG ratio of 2.32, a ROA of -11.60%, a ROC of -24.36% and a ROE of -27.18%. The company’s profit margin is -26.16%, its EBITDA margin is -15.40%, and its revenue ttm is $997.00 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Clearside Biomedical Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Clearside Biomedical Inc.’s next earnings report date is 10th May 2023.

The consensus rating of Wall Street analysts for Clearside Biomedical Inc. is Strong Buy (1.2), with a target price of $6.25, which is +531.31% compared to the current price. The earnings rating for Clearside Biomedical Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Clearside Biomedical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Clearside Biomedical Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.57, ATR14 : 0.10, CCI20 : -79.57, Chaikin Money Flow : -0.40, MACD : -0.09, Money Flow Index : 19.03, ROC : -20.31, RSI : 37.83, STOCH (14,3) : 22.50, STOCH RSI : 1.00, UO : 38.13, Williams %R : -77.50), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Clearside Biomedical Inc. in the last 12-months were: Charles A. Deignan (Option Excercise at a value of $9 454), Clay B. Thorp (Buy at a value of $14 266), Nancy J. Hutson (Buy at a value of $39 900), Thomas Ciulla (Sold 2 170 shares of value $3 515 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
1 (20.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.20
Strong Buy
1.25
Strong Buy
1.25

Clearside Biomedical Inc.

Clearside Biomedical Inc is the United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.

CEO: George Lasezkay

Telephone: +1 678 270-3631

Address: 900 North Point Parkway, Alpharetta 30005, GA, US

Number of employees: 33

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

53%47%

Bearish Bullish

61%39%


News

Stocktwits